Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Approach to find new therapies for MS from clinical view].

Rinsho shinkeigaku = Clinical neurology - 1 Nov 2008

Niino Masaaki

Abstract excerpt

Immunomodulatory drugs such as interferon beta (IFN-beta) have modestly effective in relapsing remitting multiple sclerosis (RRMS). However, all current therapies are partially effective. The cause of MS and the determinants of heterogeneity in the clinical phenotype of MS remain largely unknown and new therapeutic approaches in MS are emerging. Even now, "bench to bed" is the only approach to find new therapies....

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic Predisposition to Disease
Share to Interferon-beta
Share to Multiple Sclerosis

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Pharmacogenetics

Share to Recurrence

Source

Identifiers

PMID: 19198123
DOI: 10.5692/clinicalneurol.48.935

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Approach to find new therapies for MS from clinical view].PMID 19198123Read ↗

[MS update: risk factors, diagnosis and treatment].Semantic proximity Read ↗

[Recent prognosis on etiology and pathophysiology of multiple sclerosis].Semantic proximity Read ↗

Novel and Emerging Treatments to Target Pathophysiological Mechanisms in Various Phenotypes of Multiple Sclerosis.Semantic proximity Read ↗

United Europeans for development of pharmacogenomics in multiple sclerosis network.Semantic proximity Read ↗

Emerging small-molecule treatments for multiple sclerosis: focus on B cellsSemantic proximity Read ↗

Progressive MS: from pathophysiology to drug discoverySemantic proximity Read ↗

Multiple sclerosis: from cure to care.Semantic proximity Read ↗

Exploring Multiple Sclerosis (MS) and Amyotrophic Lateral Scler osis (ALS) as Neurodegenerative Diseases and their Treatments: A Review Study.Semantic proximity Read ↗

[Pharmacologic treatment of multiple sclerosis].Semantic proximity Read ↗

Implications for multiple sclerosis in the era of the Affordable Care Act: an evolving treatment paradigm.Semantic proximity Read ↗

Transforming growth factor β (TGF-β) pathway in the immunopathogenesis of multiple sclerosis (MS); molecular approachesSemantic proximity Read ↗

[Review of the novelties from the 2017 ECTRIMS Congress, presented at the 10th Post-ECTRIMS Meeting (I)].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.